
Opinion|Videos|July 29, 2024
Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
- Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
- What can we look forward to through the end of the year and beyond?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
5
















































